Krystal Biotech, Inc. Common Stock vs. Protara Therapeutics, Inc. Common Stock
KRYS
Krystal Biotech, Inc. Common Stock
$359.36 +2.25%
VS TARAProtara Therapeutics, Inc. Common Stock
$3.85 +0.92%
Krystal Biotech, Inc. Common Stock (KRYS) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| KRYS | TARA | |
|---|---|---|
| Market Cap | $10.40 billion | $225.74 million |
| Revenue (TTM) | $440.48 million | $3.14 million |
| Net Income (TTM) | $241.47 million | $-70,015,000 |
KRYS leads on 3 of 3 size & scale factors.
Valuation
| KRYS | TARA | |
|---|---|---|
| P/E Ratio | 45.03 | — |
| Price / Book | 7.65 | 1.40 |
| Price / Sales | 23.62 | 71.98 |
KRYS and TARA split the valuation factors evenly.
Profitability
| KRYS | TARA | |
|---|---|---|
| Net Margin | 54.82% | -2232.62% |
| Return on Equity | 17.77% | -43.40% |
KRYS leads on 2 of 2 profitability factors.
Risk & Sentiment
| KRYS | TARA | |
|---|---|---|
| Short Interest | 0.11% | 0.01% |
TARA leads on 1 of 1 risk & sentiment factors.
Dig deeper: KRYS overview, KRYS financials, TARA overview, TARA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.